{
  "id": "5c73ace87c78d69471000084",
  "type": "factoid",
  "question": "Which molecule is inhibited by ivosidenib?",
  "ideal_answer": "Ivosidenib (AG-120) is an oral, targeted, small-molecule inhibitor of mutant IDH1. It used an effective treatment of leukemia.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29266015",
    "http://www.ncbi.nlm.nih.gov/pubmed/29950729",
    "http://www.ncbi.nlm.nih.gov/pubmed/29670690",
    "http://www.ncbi.nlm.nih.gov/pubmed/29860938",
    "http://www.ncbi.nlm.nih.gov/pubmed/30209701",
    "http://www.ncbi.nlm.nih.gov/pubmed/30093505",
    "http://www.ncbi.nlm.nih.gov/pubmed/29934313"
  ],
  "snippets": [
    {
      "text": "Different combinations and new formulations of cytotoxic agents, such as clofarabine or CPX-351, are newer options for specific subsets of patients. Finally, targeted agents inhibiting multiple kinases (rigosertib), BCL2 (venetoclax) or mutant IDH1 (ivosidenib), IDH2 (enasidenib), FLT3 (sorafenib, midostaurin) or spliceosome components (H3B-8800) are other novel options.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29266015",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29670690",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Here, we report the discovery of AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29670690",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Ivosidenib (AG-120) is an oral, targeted, small-molecule inhibitor of mutant IDH1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29860938",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A phase I study suggests that ivosidenib can induce remission in patients with relapsed or refractory acute myeloid leukemia characterized by IDH1 mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29934313",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Biochemical studies predicted that resistance to allosteric IDH inhibitors could also occur via IDH dimer-interface mutations in cis, which was confirmed in a patient with acquired resistance to the IDH1 inhibitor ivosidenib (AG-120).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29950729",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The FDA approved ivosidenib for patients with IDH1-mutant relapsed/refractory acute myeloid leukemia. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30093505",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ivosidenib (Tibsovo\u00ae) is a small molecule, orally available inhibitor of mutated cytosolic isocitrate dehydrogenase 1 (IDH1) that is being developed by Agios Pharmaceuticals for the treatment of cancer in patients with IDH1 mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30209701",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of ivosidenib leading to this first approval in the USA for the treatment of patients with relapsed or refractory AML with a susceptible IDH1 mutation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30209701",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ivosidenib targets the IDH1 metabolic pathway to prevent a build-up of the oncometabolite 2-HG.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30209701",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ivosidenib (AG-120) is an oral, targeted, small-molecule inhibitor of mutant IDH1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29860938",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29860938",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "METHODS\nWe conducted a phase 1 dose-escalation and dose-expansion study of ivosidenib monotherapy in IDH1-mutated AML.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29860938",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\nIn patients with advanced IDH1-mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment-related adverse events and with transfusion independence, durable remissions, and molecular remissions in some patients with complete remission.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29860938",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we report the discovery of AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29670690",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Finally, targeted agents inhibiting multiple kinases (rigosertib), BCL2 (venetoclax) or mutant IDH1 (ivosidenib), IDH2 (enasidenib), FLT3 (sorafenib, midostaurin) or spliceosome components (H3B-8800) are other novel options.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29266015",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The FDA approved ivosidenib for patients with IDH1-mutant relapsed/refractory acute myeloid leukemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30093505",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Biochemical studies predicted that resistance to allosteric IDH inhibitors could also occur via IDH dimer-interface mutations in cis, which was confirmed in a patient with acquired resistance to the IDH1 inhibitor ivosidenib (AG-120). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29950729",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells, resulting in the production of d-2-hydroxyglutarate (2-HG), an oncometabolite. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29670690",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.In patients with advanced IDH1-mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment-related adverse events and with transfusion independence, durable remissions, and molecular remissions in some patients with complete remission. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29860938",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Ivosidenib (AG-120) is an oral, targeted, small-molecule inhibitor of mutant IDH1.<br><b>METHODS</b>: We conducted a phase 1 dose-escalation and dose-expansion study of ivosidenib monotherapy in IDH1-mutated AML.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29860938",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ivosidenib (AG-120) is an oral, targeted, small-molecule inhibitor of mutant IDH1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29860938",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We conducted a phase 1 dose-escalation and dose-expansion study of ivosidenib monotherapy in IDH1-mutated AML.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29860938",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In patients with advanced IDH1-mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment-related adverse events and with transfusion independence, durable remissions, and molecular remissions in some patients with complete remission.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29860938",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "IDH1"
}